Business Wire

Citi Global Wealth Investments Releases Outlook 2023: Roadmap to Recovery: Portfolios to Anticipate Opportunities


Citi Global Wealth Investments (CGWI) today released its Wealth Outlook 2023 (Outlook) report, titled Roadmap to Recovery: Portfolios to Anticipate Opportunities. Published twice yearly, Outlook provides in-depth insights into the global economy and financial markets for the year ahead and beyond. The latest edition’s title reflects the investing journey that CGWI envisions and the steps that investors should consider diversifying their portfolios.

In 2023, CGWI predicts the weakest annual global economic growth in forty years outside of the Global Financial Crisis and the COVID shutdowns. The year ahead is likely to see:

  • A shallow US recession and worse in some other places such as the Eurozone
  • A recovery in Chinese growth, by contrast, as pandemic restrictions are relaxed
  • US inflation continuing to ease, ending 2023 at around 3.5%
  • The US Federal Reserve to start cutting interest rates by the second half of the year
  • A 10% drop in global earnings per share

Just as 2022’s global market turmoil reflected these forecast conditions for the year ahead, investors will likely start to focus on 2024’s recovery during 2023. With the current equity bear market probably incomplete, CGWI enters the year positioned defensively, but expects to pivot as the year progresses.

“Over time, the US stock market has never bottomed before an associated recession has even begun, so we regard recent equity upside as a bear market rally,” says David Bailin, Chief Investment Officer and Head of Citi Global Wealth Investments. “A year like 2022 can make holding excess cash seem tempting, but the clear lesson of history is that this almost always leads to missing opportunities when markets begin to recover. For 2023, we reiterate the fundamental wisdom of keeping portfolios fully invested, anticipating the opportunities that we expect.”

CGWI sees a likely sequence of potential opportunities, including:

  • Short-term US investment grade fixed income amid today’s higher interest rate environment
  • Defensive equities such as resilient dividend payers as the bear market continues for now
  • Non-cyclical growth equities to bottom before cyclicals once the Fed pivots to cutting rates
  • A subsequent entry point into more cyclical equities
  • “Deep value” in select non-US assets and currencies once the US dollar peaks
  • Certain alternative strategies to position for distressed and other opportunities following the recession

“The sharp declines across many asset classes in 2022 has left long-term valuations more attractive,” said Steven Wieting, Chief Investment Strategist and Chief Economist at Citi Global Wealth Investments. “For the first time in several years, for example, we see genuine portfolio value in fixed income. Short duration US Treasuries present a compelling alternative to holding cash.”

CGWI has also updated its case for “unstoppable trends,” the powerful multi-year phenomena that continue to reshape business and everyday life, as well as portfolios. These include digitization, aging populations, the rivalry between the US and China and the transition to clean and secure sources of energy. CGWI highlights ways to seek exposure to these transformational forces in portfolios.

To access the full report, summary versions, short videos and other materials can be accessed here.

About Citi:

Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in nearly 160 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services. Additional information may be found at | Twitter: @Citi | YouTube: | Blog: | Facebook: | LinkedIn:

About Citi Global Wealth:

Citi Global Wealth is an integrated wealth management platform that delivers a total wealth solution to clients across the wealth continuum. Citi Global Wealth serves ultra-high-net-worth individuals and family offices through Citi Private Bank, operates in the affluent and high-net worth segments through Citigold® and Citigold Private Client, captures wealth management in the workplace through Global Wealth at Work and provides premium banking and lending service for clients of RIAs through Citi Alliance. Citi Global Wealth provides clients with a leading investment strategies platform, which delivers traditional and alternative investments, managed account strategies, best-in-class research and investment guidance for all clients.

To view this piece of content from, please give your consent at the top of this page.

Contact information

North America: Jamie Letica +1 646 303 4280
EMEA: Kimberley Mosley +44 20 7508 3082
APAC: Harsha Jethnani +852 2868-7738
LATAM: Denise Rockenbach +1 305 420 4304

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

European Authorities Approve Lyophilized S/D Treated Plasma OctaplasLG ® for Pre-Hospital Transfusion2.2.2023 16:28:00 CET | Press release

Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion. The line extension, which will be marketed in Europe as a powder and solvent for solution for infusion, offers new and potentially life-saving treatment options in pre-hospital and emergency settings. “The European authorization of octaplasLG® powder continues Octapharma's ongoing commitment to help prevent uncontrolled haemorrhage associated with trauma, which accounts for 30%-50% of all deaths in the first 24 hours"1-5, says Dr. Oliver Hegener, Vice President IBU Critical Care. Trauma results in 4.4 million deaths worldwide annually6, with uncontrolled bleeding being the major cause of potentially preventable death. Trauma-induced coagulopathy (TIC) is an early abnormal response characterised by hypocoagulation, in addition to acute blood loss, shock, hypothermia and metabolic aci

LTIMindtree Partners with Criteo to Drive IT Operational Efficiency2.2.2023 15:00:00 CET | Press release

LTIMindtree, a global technology consulting and digital solutions company, today announced a multi-year engagement that enables Criteo, the commerce media company, to enhance its business agility, IT service quality, and scalability. As part of the engagement, LTIMindtree provides end-to-end IT services to support Criteo’s global operations across all functions. This includes supporting Criteo’s Microsoft Azure Cloud environment, developing a unified data platform, and providing end-user services for its service desk, field, device engineering and Enterprise Service Management. “Enabling Criteo with modern IT systems and capabilities remains a key priority in this fast-moving business environment,” said Beatrice Mabille, VP Internal IT, Criteo. “We look forward to our continued strategic partnership with LTIMindtree.” “We are excited to be a part of Criteo’s business journey as its first-ever strategic IT outsourcing partner,” said Sudhir Chaturvedi, President and Executive Board Membe

Fluence Selected as LED Technology Partner by Major Cannabis Cultivators in Growing Portuguese Market2.2.2023 14:30:00 CET | Press release

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, is supporting widespread expansion of pharmaceutical-grade medical cannabis cultivation operations in Portugal. This press release features multimedia. View the full release here: Fluence LEDs in action at the Key Leaves facility in Portugal (Photo: Business Wire) Portugal’s cannabis laws are among the most progressive in the world, and its established licensing system is ahead of most other European countries. Portugal decriminalized personal cannabis use in 2001 and legalized medical use in 2018. Since then, 20 official licenses for medical cannabis production, processing, import, export or a combination of categories have been issued, and Fluence has been chosen to provide lighting for over half of them. Key Leaves, a medical cannabis market leader in Portugal, is one of the 20 companies to have received

LambdaTest Launches Digital Experience Testing Cloud to Accelerate Digital Transformation for Enterprises2.2.2023 14:00:00 CET | Press release

LambdaTest, the leading continuous quality testing cloud platform, has announced the launch of digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options. This press release features multimedia. View the full release here: LambdaTest’s digital experience testing cloud will enable enterprises to test for omnichannel experiences on custom-designed, robust, and scalable infrastructure (Graphic: Business Wire) According to Forrester’s Best Practice Report titled ‘Optimize Your Digital Experience To Compete For Customers’, “No matter how embedded your brand is in customers’ lives today, if you stop meeting their expectations, it’s easy for them to switch to a competitor tomorrow. As the ratio of digital to no

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS43182.2.2023 14:00:00 CET | Press release

Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States. The compound is in development for immunology & inflammation (I&I) indications. Bristol Myers Squibb will oversee the clinical and commercial development and Exscientia is eligible for milestone payments and, if approved, tiered royalties on net product sales. "We are excited for Bristol Myers Squibb to begin clinical evaluation of '4318, the first Exscientia I&I candidate to enter the clinic. PKC theta is an attractive immune modulating drug target; however, it has been challenging for the field to design a small molecule with the required potency as well as selectivity against other closely related kinases," said David Hallett, Ph.D., Chief Scientific Officer at Exscientia. "Our expert-led AI design platform was able to deliver a balanced candidate which has demo